AIGIV 3.5 mg/kg + Gamunex 90 mg/kg + AIGIV 7.0 mg/kg + Gamunex 180 mg/kg + AIGIV 14.0 mg/kg + Gamunex 360 mg/kg
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anthrax
Conditions
Anthrax
Trial Timeline
Feb 1, 2009 → Oct 1, 2010
NCT ID
NCT00845650About AIGIV 3.5 mg/kg + Gamunex 90 mg/kg + AIGIV 7.0 mg/kg + Gamunex 180 mg/kg + AIGIV 14.0 mg/kg + Gamunex 360 mg/kg
AIGIV 3.5 mg/kg + Gamunex 90 mg/kg + AIGIV 7.0 mg/kg + Gamunex 180 mg/kg + AIGIV 14.0 mg/kg + Gamunex 360 mg/kg is a phase 1/2 stage product being developed by Emergent BioSolutions for Anthrax. The current trial status is completed. This product is registered under clinical trial identifier NCT00845650. Target conditions include Anthrax.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00845650 | Phase 1/2 | Completed |
Competing Products
15 competing products in Anthrax
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Cipro (Ciprofloxacin, BAYQ3939) | Bayer | Pre-clinical | 20 |
| AV7909 Full Dose (0.5 mL) + AV7909 Half Dose (0.25 mL) + Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL) + Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL) | ICON plc. | Phase 2 | 49 |
| AV7909 + BioThrax | Emergent BioSolutions | Phase 3 | 69 |
| AV7909 + BioThrax | Emergent BioSolutions | Phase 2 | 44 |
| AIGIV | Emergent BioSolutions | Pre-clinical | 15 |
| CYFENDUS | Emergent BioSolutions | Pre-clinical | 15 |
| BioThrax + Ciprofloxacin | Emergent BioSolutions | Phase 2 | 44 |
| BioThrax + AV7909 Formulation 1 + AV7909 Formulation 2 + AV7909 Formulation 3 + AV7909 Formulation 4 + Control | Emergent BioSolutions | Phase 1 | 25 |
| Ciprofloxacin 500Mg Tablet + Doxycycline 100Mg Tablet + AV7909 | Emergent BioSolutions | Phase 2 | 44 |
| AVP-21D9 + Placebo | Emergent BioSolutions | Phase 1 | 25 |
| AIGIV | Emergent BioSolutions | Pre-clinical | 15 |
| AVA + Ad4-PA-1 + Ad4-PA-GPI-1 | Emergent BioSolutions | Phase 1 | 25 |
| BioThrax | Emergent BioSolutions | Phase 3 | 69 |
| Raxibacumab | Emergent BioSolutions | Phase 2/3 | 57 |
| NP-015 | Emergent BioSolutions | Phase 1 | 25 |